Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates

Core Insights - Acadia Pharmaceuticals reported quarterly earnings of $0.26 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.20 per share a year ago, resulting in an earnings surprise of +85.71% [1] - The company achieved revenues of $278.63 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.84% and increasing from $250.4 million year-over-year [2] - Acadia's stock has increased by approximately 19.1% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $284.97 million, and for the current fiscal year, it is $0.53 on revenues of $1.07 billion [7] - The estimate revisions trend for Acadia was favorable prior to the earnings release, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]